Sarcoma after 5 years of progression-free survival: Lessons from the French Sarcoma Group

Authors

  • Edwin Choy MD, PhD

    Corresponding author
    1. Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding author: Edwin Choy, MD, PhD, Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Mailstop: Yawkey 7B, 55 Fruit St, Boston, MA 02114; Fax: (617) 643-1915; echoy@partners.org

    Search for more papers by this author

  • See referenced original article on pages 3003–6, this issue.

Abstract

Because sarcomas are rare (1% of all adult solid malignancies) and encompass a heterogeneous group of tumors (> 50 subtypes), information regarding late recurrences for patients with resected soft tissue sarcomas, although recognized to occur, is not well defined. Details concerning late recurrences, such as the frequencies, risk factors, and relative rates between tumor subtypes, depend on the existence of a large, well-annotated, multiinstitutional, accurate database that spans several decades of clinical experience. The French Sarcoma Group has assembled such a database, and they report with accuracy and detail what happens to patients with sarcoma after they survive for > 5 years. Recognition that a significant percentage of long-term survivors of sarcoma are still at risk of developing late disease recurrence can be paired with the growing awareness that they are also at risk of a shortened lifespan and increased cardiovascular and psychological morbidity to highlight a critical role for long-term specialty follow-up.

Ancillary